Companies › Xizang Haisco Pharmaceutical
2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Oncology, Immunology; next expected readout Feb 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HSK44459 | – | Phase 2 | Atopic Dermatitis (AD) | – |
| HSK39775 | – | Phase 1 | Advanced Solid Tumors | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06996912 | HSK44459 | Phase 2 | Atopic Dermatitis (AD) | Immunology | Jan 2026 |
| NCT06314373 | HSK39775 | Phase 1 | Advanced Solid Tumors | Oncology | Feb 2028 |
No annotated target.
–
Tavotek Biotherapeutics Telios Pharma Molecure Antengene Biologics Ganzhou Hemay Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.